ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 159 filers reported holding ESPERION THERAPEUTICS INC NE in Q1 2021. The put-call ratio across all filers is 3.39 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $30 | -98.1% | 295,200 | 0.0% | 0.00% | – |
| Q2 2023 | $1,567 | +4135.1% | 295,200 | -7.3% | 0.00% | -100.0% |
| Q1 2023 | $37 | +48.0% | 318,500 | +1066.7% | 0.01% | +100.0% |
| Q4 2022 | $25 | -100.0% | 27,300 | -24.8% | 0.00% | -70.0% |
| Q4 2021 | $384,000 | +36.7% | 36,300 | +14.9% | 0.01% | +11.1% |
| Q3 2021 | $281,000 | +71.3% | 31,600 | +89.2% | 0.01% | +80.0% |
| Q2 2021 | $164,000 | +51.9% | 16,700 | +10.6% | 0.01% | -16.7% |
| Q1 2021 | $108,000 | +163.4% | 15,100 | -34.9% | 0.01% | +50.0% |
| Q1 2019 | $41,000 | +412.5% | 23,200 | -87.1% | 0.00% | +300.0% |
| Q4 2018 | $8,000 | -97.8% | 180,500 | -14.4% | 0.00% | -95.7% |
| Q3 2018 | $366,000 | -63.6% | 210,800 | +5.7% | 0.02% | -54.0% |
| Q2 2018 | $1,005,000 | +415.4% | 199,397 | +14.5% | 0.05% | +400.0% |
| Q1 2018 | $195,000 | +323.9% | 174,100 | +187.8% | 0.01% | +233.3% |
| Q1 2017 | $46,000 | – | 60,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital LLC | 1,637,125 | $27,684,000 | 5.54% |
| BVF INC/IL | 606,801 | $10,261,000 | 2.54% |
| Sarissa Capital Management LP | 633,000 | $10,704,000 | 2.36% |
| Glacier Peak Capital LLC | 38,048 | $989,000 | 0.85% |
| BB BIOTECH AG | 1,008,542 | $17,054,000 | 0.68% |
| FT Options LLC | 31,296 | $529,000 | 0.55% |
| Rhenman & Partners Asset Management AB | 150,000 | $2,537,000 | 0.50% |
| Virtus ETF Advisers LLC | 11,011 | $186,000 | 0.26% |
| DISCOVERY CAPITAL MANAGEMENT, LLC / CT | 806,105 | $13,631,000 | 0.20% |
| WASATCH ADVISORS LP | 759,183 | $12,519,000 | 0.19% |